1-20 of 28 results for subject:Fibroids
Librarians' tools
- Search time
- 0.246 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Fibroids
- We searched for
- subject_t:Fibroids OR subject_t:Leiomyomas OR subject_t:"Uterine fibroids" OR subject_t:"Uterine myomas" OR subject_ses:509151
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce (a) diagnostic delays and (b) higher rates of hysterectomy experienced by Black women with uterine fibroids.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce (a) diagnostic delays and (b) higher rates of hysterectomy experienced by Black women with uterine fibroids.
The Government is committed to improving care for women with uterine fibroids, and to reducing the inequalities in diagnosis and treatment that Black women experience.
Reducing inequalities is hard‑wired throughout the recently published Renewed Women’s Health Strategy. Actions in the strategy are targeted by deprivation, ethnicity, and unmet need, with a focus on marginalised women, community‑based services, neighbourhood health models, and transparent data.
The strategy commits to ending long diagnostic delays for conditions such as fibroids, by improving early assessment and access to care. It recognises heavy periods as an early warning sign of fibroids and that failure to act early leads to avoidable pain and delayed diagnosis. Specifically, the strategy commits to:
- better education for girls and women about what is normal, what is not, and when to seek help for heavy or painful periods. This is backed by an additional £1 million of investment to support targeted work in schools and community settings to support girls’ knowledge about menstrual health. This is an important factor to delays in diagnosis and treatment for fibroids;
- redesigning clinical pathways for menstrual problems, including those caused by fibroids to reduce repeat appointments and fragmented care;
- delivering care, including for fibroids, through community and neighbourhood‑based services, supported by single points of access for gynaecology referrals; and
- develop and implement new patient-reported experience measures and, where appropriate, patient-reported outcome measures, for key women’s health pathways over the next five years, which will given women a direct voice in how these services improve.
Additionally, menstrual problems, which could be a sign of fibroids, are included within the first high‑priority pathways to be supported through the new virtual hospital, NHS Online, from 2027, giving women faster access to advice and treatment if they choose digital routes.
NHS England is also due to publish an equity good practice guide to enable integrated care boards to better understand and reduce inequalities in heavy periods and menopause for women from Black and minority ethnic backgrounds.
Earlier diagnosis and better access to the full range of treatment options are central to giving women genuine choice in regard to hysterectomies. Where fibroids are identified sooner, women can be offered less invasive treatments before surgery becomes necessary. Shared decision making and informed consent mean that hysterectomy should be a fully informed choice, not a default.
Agreed to on question.
Agreed to on question.
Endometriosis, fibroids and related gynaecological conditions ruin the lives of millions of women, yet these conditions remain undiagnosed, misdiagnosed, dismissed or mistreated within the health system. Women are told to shut up and stop complaining. We are fobbed off. We experience shameful delays. We are left in pain. My argument...
Endometriosis, fibroids and related gynaecological conditions ruin the lives of millions of women, yet these conditions remain undiagnosed, misdiagnosed, dismissed or mistreated within the health system. Women are told to shut up and stop complaining. We are fobbed off. We experience shameful delays. We are left in pain. My argument...
I thank the hon. Member for taking time for this intervention on her passionate speech about the huge number of women who suffer from endometriosis. Given the challenges with diagnosis, and the enormous pain and suffering that she has outlined, does she agree that far more money and Government support...
I thank the hon. Member for taking time for this intervention on her passionate speech about the huge number of women who suffer from endometriosis. Given the challenges with diagnosis, and the enormous pain and suffering that she has outlined, does she agree that far more money and Government support...
It is nice to have a male ally in the Chamber—in fact, a few male allies. I think the issue is even wider than that. The Government are looking to publish the women’s health strategy quite soon. I will talk about this in more detail, but the data on the...
It is nice to have a male ally in the Chamber—in fact, a few male allies. I think the issue is even wider than that. The Government are looking to publish the women’s health strategy quite soon. I will talk about this in more detail, but the data on the...
I congratulate my hon. Friend the Member for Erith and Thamesmead (Ms Oppong-Asare) on securing this important debate. Baroness Merron, who leads on this work for the Department, and I are grateful to my hon. Friend for the conversations that she has been leading; for putting the spotlight on endometriosis,...
I congratulate my hon. Friend the Member for Erith and Thamesmead (Ms Oppong-Asare) on securing this important debate. Baroness Merron, who leads on this work for the Department, and I are grateful to my hon. Friend for the conversations that she has been leading; for putting the spotlight on endometriosis,...
To ask the Secretary of State for Health and Social Care, with reference to page 66 of the Women’s Health Strategy for England, published in August 2022, what steps his Department has taken to encourage research on the causes of fibroids.
To ask the Secretary of State for Health and Social Care, with reference to page 66 of the Women’s Health Strategy for England, published in August 2022, what steps his Department has taken to encourage research on the causes of fibroids.
The Department commissions research through the National Institute for Health and Care Research (NIHR). Subject to receiving high quality applications, the NIHR expects to commission a new policy research unit dedicated to reproductive health. The new unit will undertake research to inform policy in areas such as menstruation and gynaecological conditions. Applications are currently being reviewed and the unit is expected to operate from January 2024. While the NIHR has funded research on menstruation, gynaecological conditions, COVID-19, the long term effects of COVID-19 infection, mental health and the treatment of fibroids, no specific research on the relationship between these conditions has been commissioned. The NIHR welcomes funding applications for research into any aspect of human health. Applications are subject to peer review and judged in open competition, with awards made based on the importance to patients and health and care services, value for money and scientific quality. It is not usual practice for the NIHR to ring-fence a proportion of its budget for research into particular topics or conditions.
To ask the Secretary of State for Health and Social Care, what steps the Government is taking to support (a) women's health issues and (b) women with womb related health concerns including fibroids and endometriosis.
To ask the Secretary of State for Health and Social Care, what steps the Government is taking to support (a) women's health issues and (b) women with womb related health concerns including fibroids and endometriosis.
The Government has embarked on the first Government-led Women’s Health Strategy for England. To ensure the strategy reflects what women identify as priorities, we launched a call for evidence on International Women’s Day which will run for twelve weeks.
The call for evidence seeks to examine women’s experiences of the whole health and care system, including conditions that affect women, female-specific issues such as pregnancy and postnatal support and gynaecological conditions such as endometriosis and fibroids.
To ask Her Majesty's Government what assessment they have made of the European Medicines Agency's Pharmacovigilance Risk Assessment Committee's recommendation to revoke the marketing authorisation of ulipristal acetate as a treatment for uterine fibroids; and whether they intend to implement the same revocation in the UK.
To ask Her Majesty's Government what assessment they have made of the European Medicines Agency's Pharmacovigilance Risk Assessment Committee's recommendation to revoke the marketing authorisation of ulipristal acetate as a treatment for uterine fibroids; and whether they intend to implement the same revocation in the UK.
Medicines containing ulipristal acetate for the treatment of uterine fibroids were recalled from the United Kingdom market in March 2020 and no woman should have been treated with these medicines since then.
The Medicines and Healthcare products Regulatory Agency (MHRA) has assessed the data underpinning the European Union Pharmacovigilance Risk Assessment Committee's (PRAC) recommendation to revoke the marketing authorisations for ulipristal acetate 5mg for uterine fibroids. Independent advice was sought from the Commission on Human Medicines Expert Advisory Group on Medicines for Women’s Health in May 2020 and UK comments on the EU assessment reports were fed into the EU review.
The EU review for ulipristal acetate 5mg is ongoing pending a final opinion expected in October 2020 from the European Medicines Agency’s Committee for Medicinal Products for Human Use on the PRAC’s recommendation, and a decision from the European Commission within three months of the Committee for Medicinal Products Opinion. The MHRA intends to act in accordance with the outcome of the EU review.
To ask the Secretary of State for Health, what estimate he has made of the average time taken from the presentation of symptoms to a GP to the start of treatment for fibroids.
To ask the Secretary of State for Health, what estimate he has made of the average time taken from the presentation of symptoms to a GP to the start of treatment for fibroids.
NHS England publishes monthly data on referral to treatment waiting times to monitor performance against the legal right that patients have to start consultant-led treatment within a maximum of 18 weeks from referral for non-urgent conditions. The data that are published include the proportion of patients who waited within 18 high volume specialties but not individual procedures such as fibroids or benign testicular tumours. The information requested is therefore not available.
To ask the Secretary of State for Health, what steps his Department is taking to improve patient access to uterine fibroid embolisation.
To ask the Secretary of State for Health, what steps his Department is taking to improve patient access to uterine fibroid embolisation.
Uterine fibroid embolisation is a treatment that is approved and recommended by the National Institute for Health and Care Excellence.
A patient diagnosed with uterine fibroids requiring treatment will receive care and advice from their general practitioner (GP) in the first instance. If further treatment is required, the GP will refer the patient to a gynaecologist. It is the responsibility of specialist clinicians within clinical commissioning groups (CCGs) to recommend appropriate treatment to treat this condition, and for the CCGs to ensure they commission appropriate services to meet local demand.
To ask the Secretary of State for Health if he will make it his policy that the operation to remove fibroids by MR Guided Focused Ultrasound Surgery (MRgFUS) be available on the NHS.
To ask the Secretary of State for Health if he will make it his policy that the operation to remove fibroids by MR Guided Focused Ultrasound Surgery (MRgFUS) be available on the NHS.
Clinical commissioning groups (CCGs) are responsible for determining clinical commissioning policy (including the availability of, or eligibility for, NHS funded treatment) on fibroid treatments. Local CCGs decide on how to best use funding allocated to them, underpinned by clinical insight and knowledge of local health care needs.
The Department is aware that in November 2011, the National Institute for Health and Care Excellence (NICE) published Interventional Procedures Guidance [IPG413]: “Magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids”.
The Department expects CCGs to consider any relevant NICE guidance as they design services to meet the needs of patients.
(2) what assessment he has made of the (a) cost-effectiveness and (b) invasiveness of uterine fibroid embolisation as a treatment for women diagnosed with fibroids.
(2) what assessment he has made of the (a) cost-effectiveness and (b) invasiveness of uterine fibroid embolisation as a treatment for women diagnosed with fibroids.
To ask the Secretary of State for Health (1) what assessment he has made of the (a) effects of the best practice tariffs for uterine fibroid embolisation and (b) other best practice tariffs in improving quality and best practice in the NHS;
To ask the Secretary of State for Health (1) what assessment he has made of the (a) effects of the best practice tariffs for uterine fibroid embolisation and (b) other best practice tariffs in improving quality and best practice in the NHS;
(2) how he proposes that the NHS Commissioning Board will ensure that Clinical Commissioning Groups commission appropriate treatment options for women with symptomatic fibroids including minimally invasive procedures such as Uterine Artery Embolisation.
(2) how he proposes that the NHS Commissioning Board will ensure that Clinical Commissioning Groups commission appropriate treatment options for women with symptomatic fibroids including minimally invasive procedures such as Uterine Artery Embolisation.
To ask the Secretary of State for Health (1) with reference to his proposals for reform of the NHS, how he proposes that the NHS Commissioning Board will ensure that Clinical Commissioning Groups (a) follow the National Institute for Health and Clinical Excellence clinical guidance and (b) ensure that women...
To ask the Secretary of State for Health (1) with reference to his proposals for reform of the NHS, how he proposes that the NHS Commissioning Board will ensure that Clinical Commissioning Groups (a) follow the National Institute for Health and Clinical Excellence clinical guidance and (b) ensure that women...
To ask the Secretary of State for Health what steps he is taking to ensure that women with symptomatic fibroids have access to a range of treatments, including Uterine Artery Embolisation.
To ask the Secretary of State for Health what steps he is taking to ensure that women with symptomatic fibroids have access to a range of treatments, including Uterine Artery Embolisation.
To ask the Secretary of State for Health (1) what assessment has been made of the (a) economic effects and (b) effects on patients of uterine fibroid embolisation as an alternative to hysterectomy;
To ask the Secretary of State for Health (1) what assessment has been made of the (a) economic effects and (b) effects on patients of uterine fibroid embolisation as an alternative to hysterectomy;
(4) whether he plans to encourage GPs to offer uterine fibroid embolisation to women with fibroids as an alternative to hysterectomy in line with the National Institute of Health and Clinical Excellence's clinical guideline 44 on heavy menstrual bleeding.
(4) whether he plans to encourage GPs to offer uterine fibroid embolisation to women with fibroids as an alternative to hysterectomy in line with the National Institute of Health and Clinical Excellence's clinical guideline 44 on heavy menstrual bleeding.
(3) what information he plans to make available to patients with fibroids to enable them to make an informed decision about their treatment and care based on the different options available;
(3) what information he plans to make available to patients with fibroids to enable them to make an informed decision about their treatment and care based on the different options available;